Nitroflurbiprofen is a nitrosylated flurbiprofen analog under development by NicOx for the potential treatment of urinary incontinence, Alzheimer's disease (AD) and the prevention and treatment of accelerated bone resorption associated with disorders such as osteoporosis, inflammatory joint disease and Paget's disease. In addition, a topical formulation of nitroflurbiprofen is under development for the potential treatment of dermatological disorders, including contact urticaria. By 1999, nitroflurbiprofen was in phase IIa trials for urinary incontinence, Paget's disease and osteoporosis, and phase II trials of the topical formulation were underway in contact urticaria by March 2002. Phase I trials for AD had commenced by May 2003, and in September 2003, NicOx was intending to conduct further phase II trials for micturition disorders in 2003.
Lingua originaleEnglish
pagine (da-a)551-556
Numero di pagine6
RivistaCurrent Opinion in Investigational Drugs
Stato di pubblicazionePubblicato - 2004


  • NO-donor
  • drug
  • nitric oxide
  • nsaid


Entra nei temi di ricerca di 'Nitroflurbiprofen (NicOx).'. Insieme formano una fingerprint unica.

Cita questo